<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180627040251N19</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-15</date_registration>
      <primary_sponsor>Kharazmi University</primary_sponsor>
      <public_title>The effect of adding dual task to functional training on proprioception, range of motion, pain, and kinesiophobia  in people with chronic non-specific low back pain</public_title>
      <acronym></acronym>
      <scientific_title>The effect of adding dual task to functional training on proprioception, range of motion, pain, and kinesiophobia  in people with chronic non-specific low back pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91355</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a three-group randomized clinical trial with a pretest-posttest design and randomized control groups in the form of a randomized clinical trial (RCT). Eligible participants will be randomly divided into the following three groups:
Experimental Group 1: (Single-task exercise): Perform the exercise protocol without additional cognitive task.
Experimental Group 2: (Dual exercise + exercise protocol): Perform the basic low back pain exercise protocol with a simultaneous cognitive task (dual task).
Control group: An inactive intervention, Blinding description: This study is a **single-blind randomized controlled clinical trial**. The study follows a **pretest–posttest design** with two intervention groups and one control group. In this study, the outcome assessor will be blinded to group allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>chronic non-specific low back pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:(Single-task training): Performing the training protocol without additional cognitive task. Intervention 2: Intervention group: (Dual exercise + training protocol): Performing a basic back pain training protocol along with a simultaneous cognitive task (dual task). Intervention 3: Control group: No exercise intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shokouh Yousef Shanesaz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 385, Nezami Street, between Motahari and Khayyam</address>
        <city>Dezful</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6461175579</zip>
        <telephone>+98 61 4252 0083</telephone>
        <email>shanesazshokouh@gmail.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hassan Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Keshvari Sports Complex, Kosha Street, between Shohareh and Hesari, Shahid Haghani Highway, Tehran (Mirdamad neighborhood)</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>33111-15447</zip>
        <telephone>+98 21 2222 8001</telephone>
        <email>hassan.sadeghi81@yahoo.com</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of chronic non-specific low back pain by a specialist physician
Duration of pain ≥ 3 months
Age range 25 to 60 years
Self-reported pain intensity 3 to 7 using the Numeric Pain Rating Scale (NPRS)
Body mass index (BMI) less than 30 kg/m2</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of spinal surgery
Having a regular exercise program related to back pain exercises in the past 6 months
Undergoing treatment for pain or taking analgesic, anti-inflammatory, opioid or immunosuppressive drugs
If they have a motor, mental or cognitive disability, or hearing, vision or communication disorders that prevent them from completing the protocol, they will be excluded from the study
Individuals with a history of spinal trauma or fracture, cancer, (severe osteoporosis, spondyloarthropathy, spondylolisthesis, systemic inflammatory disease, illiteracy, diagnosed neurodegenerative diseases (such as Parkinson's) will be excluded from the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M54.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Low back pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:(Single-task training): Performing the training protocol without additional cognitive task</i_keyword>
      <i_keyword>Intervention group: (Dual exercise + training protocol): Performing a basic back pain training protocol along with a simultaneous cognitive task (dual task).</i_keyword>
      <i_keyword>Control group: No exercise intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Back proprioception. Timepoint: Outcome variables are measured at two time points: before and after the fatigue protocol. Method of measurement: Lumbar proprioception is assessed using a hand-held goniometer and the method of Newcomer et al. (2000). The subject, standing with eyes closed, recreates a 30-degree angle of lumbar flexion in three attempts. The mean absolute error of the three repetitions in degrees is recorded as the reconstruction error score, with higher scores indicating poorer proprioception.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Lumbar range of motion. Timepoint: Outcome variables are measured at two time points: before and after the protocol. Method of measurement: The range of motion of lumbar flexion and extension is measured using the modified Schober test. After marking reference points on the spine, the subject is asked to bend forward and backward as much as possible. The distance between the two points is measured with a tape measure, and the average of the three repetitions is recorded as the final score.</sec_outcome>
      <sec_outcome>Pain. Timepoint: Outcome variables are measured at two time points: before and after the protocol. Method of measurement: Pain intensity is measured using a visual analog scale (VAS) consisting of a 10-cm horizontal line with two ends, "no pain" (score 0) and "worst possible pain" (score 10). The subject is asked to mark a point on the line and the distance from the zero point is recorded as the pain score. This assessment will be performed at pre-test and post-test.</sec_outcome>
      <sec_outcome>Kinesiophobia. Timepoint: Outcome variables are measured at two time points: before and after the protocol. Method of measurement: kinesiophobia is measured using the Tampa Scale (TSK) consisting of 17 questions on a 4-point Likert scale (1 to 4). The range of scores varies from 17 to 68, with higher scores indicating greater fear of movement. A score of 37 or less is interpreted as low fear and a score above 37 as high fear of movement.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kharazmi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-26</approval_date>
        <contact_name>Kharazmi University Ethics Committee</contact_name>
        <contact_address>Tehran – Shahid Mofatteh Street, before Enghelab Street – No. 43. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
